RxDoctor Payments Data

Tausha Rhoades

Nurse Practitioner · Warner Robins, GANPI 1134691512

Payments from drug & device makers

$3,382in general payments, 2019–2025

Across 190 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$789
  • AbbVie$467
  • Pfizer$210
  • AstraZeneca$197
  • Lilly USA, LLC$190
  • Johnson & Johnson$122
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,27697%
  • Other$1073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,382 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$69,452
Medicare patients
166
Services billed
1,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$69,248
MounjaroTirzepatide50$65,319
EliquisApixaban36$35,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$23,203
WegovySemaglutide14$18,359
MyrbetriqMirabegron11$5,104
Levothyroxine Sodium177$1,743
Memantine Hcl ErMemantine Hcl11$1,532
SynthroidLevothyroxine Sodium15$1,223
Albuterol Sulfate HfaAlbuterol Sulfate35$979
Gabapentin90$953
Atorvastatin Calcium111$902
Omeprazole83$881
Scopolamine11$859
Rosuvastatin Calcium72$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$789$87,60757 claims
Lilly USA, LLCMounjaro$190$65,31950 claims
PfizerEliquis$210$35,21536 claims
GSKTrelegy Ellipta$119$23,20316 claims
Astellas Pharma US IncMyrbetriq$85$5,10411 claims
AbbVieSynthroid$467$1,22315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →